• Regimens, Medicines, and Physiotherapy

  Health Canada Approves Kalydeco Label Expansion for 1-2 Year-Olds

  Posted by Cystic Fibrosis News Moderator on February 4, 2019 at 9:28 am

  Health Canada has approved the label expansion of Kalydeco to be used in young children age 1-2 with certain CFTR gating mutations. Click here to find out why and how this medication may help young children with CF.

  What are your thoughts on this news? Do you agree with Health Canada’s decision?

  Cystic Fibrosis News Moderator replied 5 years, 10 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply